Article original·2026

[EN] Efficacy of the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen in a phase III trial in the DRC

New England Journal of Medicine — Vol. 394 — N° 3 — pp. e1234

Résumé

A randomized, double-blind, placebo-controlled phase III trial evaluating the efficacy of the Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine regimen among healthcare workers and at-risk populations in the Democratic Republic of the Congo.

Référence bibliographique

Référence

New England Journal of Medicine

Date de publication

2026-02-15

← Retour aux publications